ArticleThe British journal of dermatology2022

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.

Lara S van der Schoot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.